Comparative Pharmacology
Head-to-head clinical analysis: PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE versus PROMETHACON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE versus PROMETHACON.
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE vs PROMETHACON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction; promethazine is a phenothiazine derivative that blocks histamine H1 receptors and has anticholinergic, antiemetic, and sedative effects.
Promethazine is a phenothiazine derivative with antihistaminic (H1 receptor antagonist), antiemetic, sedative, and anticholinergic properties. It inhibits central and peripheral H1 receptors, blocks dopamine D2 receptors in the chemoreceptor trigger zone, and has weak alpha-adrenergic blockade.
IV: 0.1-0.5 mg phenylephrine and 12.5-25 mg promethazine as a single dose.
25-50 mg intramuscularly or intravenously every 4-6 hours as needed. Maximum intravenous rate: 25 mg/minute. Maximum daily dose: 150 mg.
None Documented
None Documented
Phenylephrine: 2-3 hours (terminal). Promethazine: 10-14 hours (terminal in adults; prolonged in elderly and hepatic impairment).
Terminal elimination half-life: 4-6 hours in healthy adults; prolonged to 10-14 hours in hepatic impairment
Phenylephrine: renal (80% as unchanged drug and sulfate conjugates). Promethazine: renal (70-80% as metabolites and unchanged drug), fecal (20-30%).
Renal (80%) as inactive metabolites, 20% fecal via bile
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine